Not All Acne Is Acne Vulgaris
Background: Acne is the most common skin disease in adolescence, with a prevalence of nearly 100%. About 60% of affected adolescents have mild acne for which they use non-prescription preparations without consulting a physician. The remaining 40% constitute the population of acne patients seen in medical practice. The course of acne can be either acute or chronic; its manifestations can appear in waves, sometimes with dramatically severe inflammation leading rapidly to scarring. Acne often has adverse emotional consequences. Its treatment is markedly better than in the past because of new pharmacological and physicochemical approaches and because evidence-based guidelines are now available.
Methods: This article is based on a selective review of the literature and also incorporates the authors’ own clinical and scientific experience.
Results: Acne vulgaris of grade I or II in an adolescent is generally not hard to treat. In contrast, the more severe grades III and IV and conglobate acne often present a therapeutic challenge, as they are associated with varying constellations of acute lesions, scarring, inflammation, and emotional disturbances. These conditions often require systemic treatment with tetracyclines, which are especially useful because of their para-antibiotic anti-inflammatory effect. Severe cases must be treated with isotretinoin. Women can benefit from anti-androgenic contraceptive drugs. Retinoids or azelaic acid are used in maintenance therapy to suppress the formation of microcomedones, the precursor stage of acne lesions.
Conclusion: A variety of effective treatments for acne are available, depending on the severity of the condition.
Apolymorphic clinical appearance (Figure 1), varying degrees of severity, acute as well as chronic forms, numerous subtypes and wide spectrum of topical and systemic treatment modalities all help define the group of diseases known as acne. The general public and many non-dermatologists consider acne a mild disease which resolves spontaneously in a matter of months to two years. A survey of 504 customers in 48 pharmacies across Germany showed that in choosing products to treat acne, 35% of patients with mild acne treated themselves, following the advice of a pharmacist (22.5%), another individual (3.3%) or relying on their own judgment (9.2%) (e1). This mild form of acne, sometimes called “physiologic acne” with relatively few “pimples” and “blackheads”, accounts for 60% of the cases, responds well to over-the-counter products and will not be further discussed in this article. Instead we will concentrate on the 40% of patients with more severe “clinical acne” who require medical treatment; they primarily are managed by dermatologists (93%) but also by general practitioners (6.3%) and pediatricians (0.6%) (e1). In addition, the complexity of acne is reflected less by acne vulgaris which refers to papulo-pustular acne of grades I–II after Plewig and Kligman, but instead by the more severe courses including nodular acne (conglobate acne), infantile acne, juvenile acne and acne tarda that occurs after the classic age range (>25 years of age) (1, 2). In addition, there are complex cases presenting as part of syndromes, secondary to hormonal disturbances, caused by medications, or as a result of provocation or continuous promotion by exogenous factors (3, e2, e3). In addition, one must separate out a wide range of acneiform dermatoses including the recently described PRIDE syndrome secondary to kinase inhibitors as well as classical rosacea, perioral dermatitis and gram-negative folliculitis.
Patients with clinical acne require medical therapy, either because of the severity or duration of their disease. Acne is the most common dermatologic diagnosis accounting for 22–32% of cases and is one of the most common reasons for visiting a physician (1.1%) (3).
In addition, acne is a socio-economic problem. In 1995 acne was the most common dermatologic diagnosis in the USA with 10.2 million cases, accounting for 25.4% of the dermatologic diagnoses of all physicians (4). The patients received 6.5 million prescriptions for a systemic acne therapy (either antibiotics or isotretinoin) yearly, costing more than 1 billion US dollars. In 2001, 2.l billion euros were spent world-wide on acne medications; this is 18.3% of the annual expenditures for treating dermatologic diseases. In 2004, the direct costs in the USA had climbed to over 2.2 billion US dollars (e4).
Scientific advances in the past 20 years have greatly contributed to a better understanding of the pathogenesis of acne and to optimizing the therapeutic approach (4–6). Numerous epidemiologic, socio-economic and psychological aspects of acne have at the same time been extensively evaluated (7–12).
- Classification of clinical acne according to degree of severity as prerequisite for choice of therapy
- Using topical and systemic agents and combinations thereof according to guideline recommendations
- Awareness of the psychosomatic and psychiatric complications of acne, the special variants and the problems young acne patients have with compliance.
This article reflects the experience of the authors, the German S2k and the European S3 guidelines for acne, numerous personal experimental and clinical studies and as well as an extensive selective review of the national and international literature.
Acne is an almost universal disease (8, 10, 13); nonetheless, its prevalence has been estimated as 0% in rural Brazil (e5) and 100% among children and adolescents in the UK (e6). Acne’s prevalence peaks between age 14 and the start of the 3rd decade (8, 9).
Some 20–40% of the cases persist past the age of 25 years. In a survey of 48 665 employees in Germany, the over-all prevalence of acne was 4.2% (9); in the sub-analysis the prevalence in the age group 16–20 years was 24.8%. Other studies show a prevalence in adolescents between 9 and 20 years of up to 95%, without separating clinical from “physiologic” acne. As long ago as 1931, a Swiss study reported a prevalence of 88–99% in young men and 88–97% in young women (e7). An English study in 1971 yielded similar results (e6); in Sweden large studies in school children showed a prevalence of clinical acne among 15–16 year olds of 50–54% in boys and 37–39% in girls (e8, e9). The prevalence of moderately severe acne among 15–24 year olds was about 14% (e10).
In a population-based epidemiological study in Hamburg, the prevalence among men was 29.9% and among women 23.7% for a group with a median age of 42 years (e11). Additional studies indicate that up to 40% of women over 25 years of age still have acne, even though the natural course of acne is to exhibit regression by this age (e12). Three well-documented studies show a prevalence of late-type acne especially in patients with a genetic predisposition to be as high as 50–53% (e13–e15). Prospective cohort studies in China (e16), France (e17) and Great Britain (e18) show that familial predisposition is associated with severe forms of acne and persistence into the 3rd decade (odds ratio 3.5), Familial predisposition and especially acne in the mother are significantly associated with a more severe course (10).
Twin studies show identical sebum production in monozygotic twins, of up to 98% (e18). In a study involving 458 monozygotic and 1099 dizygotic twins, 81% (95% confidence interval [CI], 73–87%) of the variability in disease severity was attributed to genetic factors and 19% to environmental or epigenetic factors (e19). Exogenous factors such as androgenic hormones, competitive sports, nicotine and diet with a high hyperglycemic index make the natural course of acne more severe and persistent (4, 5, 8). Well-documented large cohort studies show no association between acne and obesity, instead suggesting that the content of the diet is more important. In the Glasgow alumni cohort study, students with and without a history of acne were compared; a positive acne history correlated with a clearly reduced risk of coronary artery disease but a higher risk for prostate cancer (e20).
A wide variety of clinical patterns can be observed. The most common course is a gradual development of clinically apparent disease, which can last months up to a year, then a continuous phase with occasional flares, and finally a slow regression at the end of the 2nd decade or beginning of 3rd decade. This classical pattern has different variants with more rapid onset and greater severity which reach a plateau, then wax and wane depending on the topical and systemic therapy, and finally undergo natural regression (1, 7). The most disastrous forms are those associated with dramatic progression, maximal inflammation, and a tendency to early scarring; they involve papulo-pustular nodular acne (grade IV) and/or conglobate acne. Each clinical course is unique and influenced by the type of therapeutic intervention. Other patients follow the typical course of papulo-pustular acne grade I–II or chronic inflammatory acne grade III after Plewig and Kligman. The former group often responds well to long-term continuous topical therapy. Finally there are some patients, usually young men, who after a chronic mild course flare dramatically at age 17–18 years.
Even though all forms that start at puberty are associated with elevated androgen [dehydroepiandrosterone sulfate [DHEA-S)] levels, there is no long-term study that correlates androgen levels prior to, at the start of, and throughout puberty with clinical features of acne. Elevation of DHEA-S levels is best documented in women in the 3rd decade. In addition, it is becoming clearer that acne is not a short-term problem but a chronic disease with persistent inflammation over years (7). Many different courses may be observed—clear improvement and then severe relapse, sudden flares, or gradual re-occurrence. Finally the psycho-social aspects of the disease are of great importance for the patients in dealing with their family, partner and friends, as well as coping at school, when starting college or entering the job market (11). For this reason acne has been re-classified in recent years as a chronic inflammatory disease, similar to atopic dermatitis (7) (Table 1). The course of acne confirms to both the older and the most recent definitions of chronicity from the World Health Organization (WHO) (7). In particular, the number of acne patients outside the classic age range, as in acne tarda (14, e11), is increasing. Here one may encounter cases that after naturally regressing flare again in the second half of the 3rd decade, others that never clear, and still others that first become apparent during the 3rd decade. Frequently the patient is a woman who has used hormonal contraception since puberty and then in the 3rd decade stops contraception because of a desire to have children, but develops both increasing amount of sebum and acne of varying degrees of severity (e11).
The classic concept is that acne results from the combination of increased sebaceous gland activity with seborrhea, abnormal follicular differentiation with increased keratinization, microbial hyper-colonization of the follicular canal and increased inflammation primarily through activation of the adaptive immune system. New research results have led to a modification of this classical explanation as more primary pathophysiologic factors have been identified.
Along with a genetic predisposition, other major factors include androgens, pro-inflammatory lipids as ligands of sebocyte peroxisome proliferator-activated receptors (PPAR), and other inflammatory pathways. In addition, neuroendocrine regulatory mechanisms, diet and exogenous factors all may contribute to this multi-factorial process (3–5) (Figure 2).
Cyclic growth of sebaceous follicles and triggers of inflammatory cascade
The hyperproliferation of the follicular epithelium leads to the development of microcomedones. Although clinically not visible, these are the initial lesions in acne and can be found in apparently normal skin of acne patients (e21). It has been proposed that the sebaceous follicles go through a cyclic pattern leading to spontaneous resolution of the microcomedones (e22–e25). Bioactive interleukin (IL)-1 is found in open comedones of untreated patients (e26). There is no correlation between the cytokine level and the number of follicular microbes. Overstimulation of subclinical inflammatory process or lack of negative feedback regulation could be the reasons for the interruption of the normal cyclic process and for the development of clinically relevant follicular inflammation in acne (4, 6).
Androgens—especially DHEA-S—play an important role in the early pathogenesis of acne, leading to larger sebaceous glands with increased sebum production (14, e27, e28). In addition, androgens stimulate the keratinocytes of the sebaceous duct (progenitor cells) and infundibulum (e29–e31). Excessive androgen production leads to increased sebum production and acne of varying severity (e32). Skin not responsive to androgens produces no sebum and develops no acne (e33, e34).When follicles lack androgen receptors, they can develop seborrhea but no comedones or inflammatory acne lesions (for example, familial nevoid sebaceous gland hyperplasia).
Lipid synthesis requires androgens and peroxisome proliferator-activated receptors (PPAR) (e35). Neuropeptides (with hormonal and non-hormonal actions) can control the development of clinical inflammation in acne (neurogenic co-control) (15). Substance P can be identified in numerous immune-reactive nerve fibers of acne skin (e36) and sebaceous glands respond to it with the synthesis of the inactivating neutral endopeptidase.
In recent years a dietary hypothesis for the pathogenesis of acne has been brought forward (e40–e44). The relationship between hyperinsulinemia and elevated IGF-1 and reduced IGF-BP has been increasingly supported by controlled cohort studies. The relationship between the number of cigarettes smoked daily and the severity of acne is controversial (e11, e20, e45, e46).
Synthesis of chemokines and cytokines by keratinocytes can be stimulated by certain Propionibacterium acnes (P. acnes) strains through the activation of toll-like receptor 2 (e47–e49). P. acnes must first develop a biofilm to become a relevant pathogen, then playing an important role in maintaining inflammation (e50, e51).
The treatment of acne was slow to profit from the development of new topical and systemic medications. (17, e52–e54). After tretinoin in 1962, two additional topical retinoids became available in the 1980s and 1990s, namely isotretinoin and adapalene. The latter is a rexinoid (RAR/RXR/VDR) whose development was made possible by a better understanding of the cytoplasmic and nuclear retinoid receptors and their control of gene expression (18). In the mid-1980s, azelaic acid, a dicarboxylic acid, was introduced into topical therapy. The use of systemic antibiotics in acne therapy was originally based on the knowledge that oral tetracycline could inhibit experimentally induced pustules (19). Initially the goal was to suppress P. acnes. Today antibiotic treatment of acne is undergoing a paradigm change, as one shifts to a sub-anti-microbial dose of 40 mg daily in a delayed release formulation, using the para-antibiotic, anti-inflammatory action of these substances (doxycycline, minocycline) (e55). Oral erythromycin is almost exclusively reserved for severe acne during pregnancy (1, 2). With the development of the anti-androgenic substances cyproterone acetate and chlormadinone acetate, additional options for women with severe acne became available (14, 20). The development of the spironolactone derivative drospirenone as a component of 4th generation oral contraceptives was the last advance in this area, but enthusiasm has been dampened because of the apparent increased risk of thrombosis.
Because of increasing resistance of P. acnes, there are worldwide efforts to replace topical antibiotics with BPO, topical retinoids and azelaic acid, or combinations thereof (17, 19). Since acne is a disease that tends to recur, maintenance therapy to suppress the development of the precursor microcomedones that lead to both inflammatory and non-inflammatory acne lesions is desirable; numerous evidence-based studies in recent years have shown that topical retinoids can accomplish this (1, 2, 18). Physical and chemical treatment methods for acne have not been adequately studied with evidence-based methods (21). Irradiation with blue or blue-red light destroys P. acnes via an endogenous porphyrin activation leading to cell death. UVA irradiation is comedogenic, while treatment with UVB irradiation is obsolete. The effects of interventional therapy with lasers, chemical peels, fillers or photodynamic therapy have not been sufficiently studied (21–23) (Table 2). The latter are especially suitable for treating the late manifestations of acne, such as hypertrophic and atrophic scars, as well as post-inflammatory hyperpigmentation. The Global Alliance for Better Outcomes in Acne, formed in 2001, organizes regional conferences in Asia, Europe, South America and North America, as well as national acne study groups, in order to develop guidelines and enhance evidence-based studies. The S2k acne guidelines published in Germany in 2010 (1) were the basis for the 2012 European S3 guidelines which are now being advanced to global guidelines (2). They are summarized in Table 3; these are only general recommendations which can be modified and personalized by the treating physicians taking into account the complex nature and variable course of acne.
Based on these guidelines (1, 2) topical monotherapy with antibiotics is not recommended. Instead, topical combination therapy with BPO is recommended for mild papulo-pustular acne. Topical retinoids are recommended as monotherapy for comedonal acne or in combination with BPO or topical antibiotics for milder papulo-pustular acne (Table 2). Topical azelaic acid therapy is the second-line recommendation for comedonal and mild papulo-pustular acne. Topical corticosteroids should not be used in treating acne (Table 3).
Combination therapy with topical drugs and oral antibiotics (doxycycline > minocycline, tetracycline) is recommended for moderate to severe acne, as well as less severe inflammatory acne which fails to respond to topical therapy alone. The systemic antibiotics should not be used alone but instead in combination with topical retinoids, BPO or azelaic acid. For women, oral contraceptives containing anti-androgens are another option. The recommended antibiotic dosages are doxycycline 50 mg daily–b.i.d. to 100 mg b.i.d., minocycline 50 mg b.i.d., tetracycline 500 mg b.i.d., and erythromycin 500 mg b.i.d.; therapy can be continued for three months (Table 4).
Hormonal anti-androgen therapy is not recommended as a first-line monotherapy for uncomplicated acne. Ethinylestradiol in combination with cyproterone acetate, chlormadinone acetate, dienogest or drospirenone is recommended only as a combination therapy for women with moderate papulo-pustular acne to conglobate acne (14, 19).
Systemic corticosteroids can play a role in the initial therapy of severe inflammatory acne, in patients with systemic inflammatory manifestations (such as acne fulminans), or to control exacerbations during systemic isotretinoin therapy.
Maintenance therapy with topical retinoids (adapalene > isotretinoin, tretinoin) or azelaic acid is also recommended.
During pregnancy and nursing, possible treatment options include topical therapy with BPO, azelaic acid, erythromycin and chemical peels, as well as lasers and phototherapy. Systemic erythromycin, zinc and corticosteroids can be used in adjusted dosages in severe flares. Topical retinoids and clindamycin are contraindicated during pregnancy.
Therapy with oral isotretinoin: comments
Isotretinoin is without question the most effective oral agent for severe acne (papulo-pustular nodular acne, conglobate acne) (24, e56–e58) (Figure 3). Since its introduction in the 1980s and the detailed knowledge of its side effects, there have been repeated controversies over the indications for its use. Until the beginning of 2002, the above indications were well-accepted and it was understood among physicians experienced in treating acne that isotretinoin—including low-dose therapy—was not indicated in patients with mild acne. The EMA (European Medicines Agency) altered the recommendations at that time, requiring a trial of oral and topical medications in combination; if this failed, then isotretinoin could be employed. The registered indications were correspondingly altered. Physicians worldwide reacted differently then and continue to do so, basing their actions on many years of experience. The authors presented the arguments for isotretinoin as first choice treatment for severe acne to the EMA (25). Dermatologists in private practice and other physicians are in a position of conflict since the publication of the European S3 guidelines, as this document once again recommends isotretinoin as the drug of choice for severe acne (papulo-pustular nodular acne and conglobate acne). The feeling is that the sooner isotretinoin is employed for acne with marked inflammation and a tendency to early scarring, the better it is for the patient. The recommended doses are 0.3–0.5 mg/kg body weight (BW) for severe papulo-pustular nodular acne and ≥0.5 mg/kg BW for conglobate acne; therapy should be continued for 6 months, sometimes even longer (24) (Table 5).
rundschrift_mit_Einzug">In addition to the risk of teratogenicity with systemic retinoid therapy—just as with high-dose vitamin A administration—one must pay careful attention to the possible induction of depression and suicidal ideation. This problem has only been reported when isotretinoin was used to treat acne, not when it has been employed to treat ichthyosis or psoriasis (it was used extensively for the latter indication in the USA prior to the introduction of etretinate and acitretin). Prospective cohort studies have shown that acne patients tend to have suicidal ideation as well as depression because of their altered appearance and psychosocial complications (26, e71). During treatment with oral antibiotics, however, suicide and depression were found to be just as common as under treatment with oral antibiotics and in controls (e72). Nonetheless every patient starting on isotretinoin must be assessed for a risk of depression, counselled and then followed closely. Recently, it has been noted that patients treated with high doses of isotretinoin and with repeated cycles have a greater risk of inflammatory colitis but not Crohn disease (27, e73–e75). The risk of rhabdomyolysis has been known for 30 years and is small, but every patient should be warned not to engage in over-strenuous activity at work or sports. Clinical observation and laboratory monitoring are recommended.
Conflict of interest statement
Prof. Gollnick has participated in acne-relevant clinical and experimental studies, symposia and advisory boards of Galderma, Stiefel/GSK, Intendis, Meda, Merz, Hoffmann-LaRoche, Novartis, Schering, Pierre Fabre, IMTM, and Vichy.
Prof. Zouboulis has patents and receives royalties for “Sebocytes, sebocyte cell lines and applications thereof” DE19991003920 as well as “Acne treatment with lipoxygenase inhibitors” DE20011021252. He has served as a paid advisor to Bayer-Schering, Boehringer-Ingelheim, Dermira, Galderma, Intendis, Leo, Merz, and Stiefel/GSK. He has received honoraria for publications from BASF. He has received reimbursement for travel and accomodation costs from Bioderma, General Topics, Glenmark, and Stiefel/GSK. He has received honoraria for organizing scientific continuing medical education symposia from Bayer/Schering, Bioderma, General Topics, Glenmark, and Stiefel/GSK. He has received honoraria for clinical studies from Galderma, Merz, and Stiefel/GSK. He has received honoraria for experimental research projects which he initiated from Galderma, Hoffmann-LaRoche, and MSD.
Manuscript received on 6 March 2013, revised version accepted on
19 March 2014.
Translated from the original German by Walter H.C. Burgdorf, MD
Prof. Dr. med. Harald P. Gollnick
Universitätsklinik für Dermatologie und Venerologie
Otto-von-Guericke Universität Magdeburg
Leipziger Str. 44
39120 Magdeburg, Germany
@For eReferences please refer to:
Isotretinoin und chronisch-entzündliche Darmerkrankung.
Dtsch Arztebl 2012; 109: A-1044. VOLLTEXT
Departments of Dermatology, Venereology, Allergology and Immunology, Dessau Medical Center:
Prof. Dr. med. Dr. h.c. Zouboulis
|1.||Nast A, Bayerl C, Borelli C, et al.: S2k-Leitlinie zur Therapie der Akne. J Dtsch Dermatol Ges 2010; 8(Suppl 2): 1–59. MEDLINE CrossRef|
|2.||Nast A, Dréno B, Bettoli V, et al.: European evidence-based (S3) guidelines for the treatment of acne. J Eur Acad Dermatol Venereol 2012; 26(Suppl 1): 1–29. MEDLINE CrossRef|
|3.||Zouboulis CC: Acne and sebaceous gland function. Clin Dermatol 2004; 22: 360–6. MEDLINE CrossRef|
|4.||Zouboulis CC, Eady A, Philpott M, et al.: What is the pathogenesis of acne? Exp Dermatol 2005; 14: 143–52. MEDLINE CrossRef|
|5.||Kurokawa I, Danby FW, Ju Q, et al.: New developments in our understanding of acne pathogenesis and treatment. Exp Dermatol 2009; 18: 821–32. MEDLINE CrossRef|
|6.||Zouboulis CC: Moderne Aspekte der Aknepathogenese. J Dtsch Dermatol Ges 2010; 8(Suppl 1): 7–14. MEDLINE CrossRef|
|7.||Gollnick HP, Finlay AY, Shear N; Global Alliance to Improve Outcomes in Acne: Can we define acne as a chronic disease? If so, how and when? Am J Clin Dermatol 2008; 9: 279–84. MEDLINE CrossRef|
|8.||Schäfer T, Kahl C, Rzany B: Epidemiologie der Akne. J Dtsch Dermatol Ges 2010; 8(Suppl 1): 4–6. MEDLINE CrossRef|
|9.||Schaefer I, Rustenbach SJ, Zimmer L, Augustin M: Prevalence of skin diseases in a cohort of 48,665 employees in Germany. Dermatology 2008; 217: 169–72. MEDLINE CrossRef|
|10.||Ghodsi SZ, Orawa H, Zouboulis CC: Prevalence, severity and severity risk factors of acne in high school pupils: A community-based study. J Invest Dermatol 2009; 129: 2136–41. MEDLINE CrossRef|
|11.||Niemeier V, Kupfer J, Gieler U: Akne vulgaris – Psychosomatische Aspekte. J Dtsch Dermatol Ges 2010; 8(Suppl 1): 95–104. MEDLINE CrossRef|
|12.||Radtke MA, Schäfer I, Augustin M: Pharmakoökonomie der Akne – Bewertung von Nutzen und Wirtschaftlichkeit. J Dtsch Dermatol Ges 2010; 8 (Suppl 1): 1055–114. MEDLINE CrossRef|
|13.||Jemec GB, Linneberg A, Nielsen NH, Frolund L, Madsen F, Jorgensen T: Have oral contraceptives reduced the prevalence of acne? A population-based study of acne vulgaris, tobacco smoking and oral contraceptives. Dermatology 2002; 204: 179–84. MEDLINE CrossRef|
|14.||Zouboulis CC: Acne vulgaris – Rolle der Hormone. Hautarzt 2010; 61: 107–14 MEDLINE CrossRef|
|15.||Thielitz A, Gollnick H: Overview of new therapeutic developments for acne. Expert Rev Dermatol 2009; 4: 55–65. CrossRef|
|16.||Ganceviciene R, Graziene V, Fimmel S, Zouboulis CC: Involvement of the corticotropin-releasing hormone system in the pathogenesis of acne vulgaris. Br J Dermatol 2009; 160: 345–52. MEDLINE CrossRef|
|17.||Fluhr JW, Degitz K: Antibiotika, Azelainsäure und Benzoylperoxid in der topische Aknetherapie. J Dtsch Dermatol Ges 2010; 8(Suppl 1): 24–30. MEDLINE CrossRef|
|18.||Thielitz A, Abdel-Naser MB, Fluhr JW, Zouboulis CC, Gollnick H: Topische Retinoide bei Akne – eine evidenzbasierte Übersicht. J Dtsch Dermatol Ges 2010; 8(Suppl 1): 15–23. MEDLINE CrossRef|
|19.||Ochsendorf F: Systemische Antibiotika zur Behandlung der Acne vulgaris. J Dtsch Dermatol Ges 2010; 8(Suppl 1): 31–46. MEDLINE CrossRef|
|20.||Zouboulis CC, Rabe T: Hormonelle Antiandrogene in der Aknetherapie. J Dtsch Dermatol Ges 2010; 8(Suppl 1): 60–74. MEDLINE CrossRef|
|21.||Degitz K, Plewig G, Gollnick H: Ergänzende Verfahren in der Aknetherapie – Aktualisierung 2010. J Dtsch Dermatol Ges 2010; 8(Suppl 1): 75–80. MEDLINE CrossRef|
|22.||Bayerl C, Degitz K, Meigel E, Kerscher M: Adjuvante dermatokosmetische Aknetherapie. J Dtsch Dermatol Ges 2010; 8(Suppl 1): 89–94. MEDLINE CrossRef|
|23.||Jansen T, Podda M: Therapie der Aknenarben. J Dtsch Dermatol Ges 2010; 8(Suppl 1): 81–8. MEDLINE CrossRef|
|24.||Ganceviciene R, Zouboulis CC: Isotretinoin: state of the art treatment for acne vulgaris. Expert Rev Dermatol 2007; 2: 693–706. CrossRef|
|25.||Layton AM, Dreno B, Gollnick HPM, Zouboulis CC: A review of the European directive for prescribing systemic isotretinoin for acne vulgaris. J Eur Acad Dermatol Venereol 2006; 20: 773–6. MEDLINE CrossRef|
|26.||Marqueling AL, Zane LT: Depression and suicidal behavior in acne patients treated with isotretinoin: a systematic review. Semin Cutan Med Surg 2007; 26: 210–20. MEDLINE CrossRef|
|27.|| Arzneimittelkommission der Deutschen Ärzteschaft: |
Isotretinoin und chronisch-entzündliche Darmerkrankung.
Dtsch Arztebl 2012; 109: A-1044. VOLLTEXT
|e1.||Franzke N, Zimmer L, Schäfer I, Radermacher C, Kresken J, Augustin M: Quality of medical care of patients with acne vulgaris in Germany – nationwide survey of pharmacy clients. J Dtsch Dermatol Ges 2009; 7: 1060–3. MEDLINE|
|e2.||Zouboulis CC: Moderne Aspekte der Aknepathogenese. Akt Dermatol 2006; 32: 296–302.|
|e3.||Chen W, Obermayer-Pietsch B, Hong J-B, et al.: Acne-associated syndromes: Models for better understanding of acne pathogenesis. J Eur Acad Dermatol Venereol 2011; 25: 637–46. MEDLINE CrossRef|
|e4.||Bickers DR, Lim HW, Margolis D, et al.: The burden of skin diseases: 2004 a joint project of the American Academy of Dermatology Association and the Society for Investigative Dermatology. J Am Acad Dermatol 2006; 55: 490–500. MEDLINE CrossRef|
|e5.||Bechelli L, Haddad N, Pimenta W, et al.: Epidemiological survey of skin diseases in schoolchildren living in the Purus Valley (Acre State, Amazonia, Brazil). Dermatologica 1981; 163: 78–93. MEDLINE CrossRef|
|e6.||Burton JL, Cunliffe WJ, Stafford I, et al.: The prevalence of acne vulgaris in adolescence Br J Dermatol 1971; 85: 119–26 MEDLINE CrossRef|
|e7.||Bloch B: Metabolism, endocrine glands and skin diseases, with special reference to acne vulgaris and xanthoma. Br J Dermatol 1931; 43: 77–87.|
|e8.||Hellgren L: A preliminary report of the prevalence of seborrhoeic dermatitis, acne vulgaris and warts in the county of Skaraborg in Sweden. Acta Derm Venerel (Stockh) 1963; 43: 502–9.|
|e9.||Larsson PA, Liden S: Prevalence of skin diseases among adolescents 12–16 years of age. Acta Derm Venereol 1980: 60: 415–23 MEDLINE|
|e10.||Rea J, Newhouse M, Halil T: Skin disease in Lambeth. A community study of prevalence and use of medical care. Br J Prev Soc Med 1976; 30: 107–14 MEDLINE PubMed Central|
|e11.||Schäfer T, Nienhaus A, Vieluf D, Berger J, Ring J: Epidemiology of acne in the general population: the risk of smoking. Br J Dermatol 2001; 145: 100–4 MEDLINE CrossRef|
|e12.||Dréno B, Layton A, Zouboulis CC, et al.: Adult female acne: a new paradigm. J Eur Acad Dermatol Venereol, 2013 Sep; 27: 1063–70 MEDLINE|
|e13.||Knaggs HE, Wood EJ, Rizer RL, Mills OH: Post-adolescent acne. Int J Cosmet Sci 2004; 26: 129–38 MEDLINECrossRef|
|e14.||Goulden V, McGeown CH, Cunliffe WJ: The familial risk of adult acne: a comparison between first–degree relatives of affected and unaffected individuals. Br J Dermatol 1999; 14: 297.|
|e15.||Dumont-Wallon G, Dréno B: Acné de la femme de plus de 25 ans: spécifique par sa clinique et les facteurs favorisants: Étude rétrospective de 79 femmes. Presse Med 2008; 37: 585–91 MEDLINECrossRef|
|e16.||Shen Y, Wang T, Zhou C, et al.: Prevalence of acne vulgaris in Chinese adolescents and adults: a community-based study of 17,345 subjects in six cities. Acta Derm Venereol 2012; 92: 40–4 MEDLINE CrossRef|
|e17.||Collier CN, Harper JC, Cafardi JA, et al.: The prevalence of acne in adults 20 years and older. J Am Acad Dermatol 2008; 58: 56–9 MEDLINECrossRef|
|e18.||Walton S, Wyatt EH, Cunliffe WJ: Genetic control of sebum excretion and acne—a twin study. Br J Dermatol 1988; 118: 393–6 CrossRef|
|e19.||Bataille V, Snieder H, MacGregor AJ, Sasieni P, Spector TD: The influence of genetics and environmental factors in the pathogenesis of acne: a twin study of acne in women. J Invest Dermatol 2002; 119: 1317–22 MEDLINE CrossRef|
|e20.||Galobardes B, Smith GD, Jeffreys M, Kinra S, McCarron P: Acne in adolescence and cause-specific mortality: Lower coronary heart disease but higher prostate cancer mortality. The Glasgow Alumni Cohort Study. Am J Epidemiol 2005; 161: 1094–101 MEDLINE CrossRef|
|e21.||Norris JF, Cunliffe WJ: A histological and immunocytochemical study of early acne lesions. Br J Dermatol 1988; 118: 651–9 CrossRef|
|e22.||Cunliffe WJ, Holland DB, Clark SM, Stables GI: Comedogenesis: some new aetiological, clinical and therapeutic strategies. Br J Dermatol 2000; 142: 1084–91 CrossRef|
|e23.||Xu Y, Yang L, Yang T, Xiang M, Huang E, Lian X: Expression pattern of cyclooxygenase-2 in normal rat epidermis and pilosebaceous unit during hair cycle. Acta Histochem Cytochem 2008; 41: 157–63 MEDLINE PubMed Central CrossRef|
|e24.||Jeremy AHT, Holland DB, Roberts SG, Thomson KF, Cunliffe WJ: Inflammatory events are involved in acne lesion initiation. J Invest Dermatol 2003; 121: 20–7 MEDLINE CrossRef|
|e25.||Zouboulis CC: Is acne vulgaris a genuine inflammatory disease? Dermatology 2001; 203: 277–9 MEDLINE CrossRef|
|e26.||Ingham E, Eady EA, Goodwin CE, Cove JH, Cunliffe WJ: Pro-inflammatory levels of interleukin-1 alpha-like bioactivity are present in the majority of open comedones in acne vulgaris. J Invest Dermatol 1992; 98: 895–901 CrossRef|
|e27.||Pochi PE, Strauss JS: Sebaceous gland response in man to the administration of testosterone, D4-androstenedione, and dehydroisoandrosterone. J Invest Dermatol 1969; 52: 32–6 MEDLINE|
|e28.||Chen W, Yang CC, Liao CY, et al.: Expression of sex-determining genes in human sebaceous glands and their possible roles in pathogenesis of acne. J Eur Acad Dermatol Venereol 2006; 20: 846–52 MEDLINE|
|e29.||Cunliffe W, Forster R: Androgen control of the pilosebaceous duct? Brit J Dermatol 1987; 116: 449.|
|e30.||Zouboulis CC: The sebaceous gland in adolescent age. Eur J Ped Dermatol 2008; 18: 150–4.|
|e31.||Lucky AW, Biro FM, Huster GA, Leach AD, Morrison JA, Ratterman J: Acne vulgaris in premenarchal girls. Arch Dermatol 1994; 130: 308–14 MEDLINE|
|e32.||Stewart ME, Downing DT, Cook JS, Hansen JR, Strauss JS: Sebaceous gland activity and serum dehydroepiandrosterone sulfate levels in boys and girls. Arch Dermatol 1992; 128: 1345–8 CrossRef|
|e33.||Marynick SP, Chakmajian ZH, McCaffree DL, Herdon JH: Androgen excess in cystic acne. N Engl J Med 1983; 308: 981–6 MEDLINE CrossRef|
|e34.||Imperato-McGinley J, Gautier T, Cai LQ, Yee B, Epstein J, Pochi P: The androgen control of sebum production. Studies of subjects with dihydrotestosterone deficiency and complete androgen insensitivity. J Clin Endocrinol Metabol 1993; 76: 524–8 MEDLINE|
|e35.||Alestas T, Ganceviciene R, Fimmel S, Müller-Decker K, Zouboulis CC: Enzymes involved in the biosynthesis of leukotriene B4 and prostaglandin E2 are active in sebaceous glands. J Mol Med 2006; 84: 75–87 MEDLINE CrossRef|
|e36.||Toyoda M, Nakamura M, Makino T, Kagoura M, Morohashi M: Sebaceous glands in acne patients express high levels of neutral endopeptidase. Exp Dermatol 2002; 11: 241–7 CrossRef|
|e37.||Alesci S, Bornstein SR: Neuroimmunoregulation of androgens in the adrenal gland and the skin. Horm Res 2000; 54: 281–6 CrossRef|
|e38.||Slominski AT, Botchkarev V, Choudhry M, et al.: Cutaneous expression of CRH and CRH-R. Is there a „skin stress response system?“. Ann N Y Acad Sci 1999; 885: 287–311 MEDLINE CrossRef|
|e39.||Zouboulis CC: The human skin as a hormone target and an endocrine gland. Hormones 2004; 3: 9–26 CrossRef|
|e40.||Letawe C, Boone M, Pierard GE: Digital image analysis of the effect of topically applied linoleic acid on acne microcomedones. Clin Exp Dermatol 1998; 23: 56–8 CrossRef|
|e41.||Melnik BC: Diet in acne: further evidence for the role of nutrient signalling in acne pathogenesis. Acta Derm Venereol 2012; 92: 228–31 MEDLINE CrossRef|
|e42.||Cordain L, Lindeberg S, Hurtado M, Hill K, Eaton SB, Brand-Miller J: Acne vulgaris: a disease of Western civilization. Arch Dermatol 2002; 138: 1584–90 MEDLINE|
|e43.||Smith RN, Mann NJ, Braue A, Mäkeläinen H, Varigos GA: A low-glycemic-load diet improves symptoms in acne vulgaris patients: a randomized controlled trial. Am J Clin Nutr 2007; 86: 107–15 MEDLINE|
|e44.||Adebamowo CA, Spiegelman D, Berkey CS, et al.: Milk consumption and acne in teenaged boys. J Am Acad Dermatol 2008; 58: 787–93 MEDLINE CrossRef|
|e45.||Firooz A, Sarhangnejad R, Davoudi SM, Nassiri-Kashani M: Acne and smoking: is there a relationship? BMC Dermatol 2005; 5: 2 MEDLINE PubMed Central CrossRef|
|e46.||Klaz I, Kochba I, Shohat T, Zarka S, Brenner S: Severe acne vulgaris and tobacco smoking in young men. J Invest Dermatol 2006; 126: 1749–52 MEDLINE CrossRef|
|e47.||Kim J, Ochoa MT, Krutzik SR, et al.: Activation of toll-like receptor 2 in acne triggers inflammatory cytokine responses. J Immunol 2002; 169: 1535–41 MEDLINE|
|e48.||Pivarcsi A, Bodai L, Rethi B, et al.: Expression and function of Toll-like receptors 2 and 4 in human keratinocytes. Int Immunol 2003; 15: 721–30 MEDLINE CrossRef|
|e49.||Nagy I, Pivarcsi A, Koreck A, Szell M, Urban E, Kemény L: Distinct strains of Propionibacterium acnes induces selective human b–defensin-2 and interleukin-8 expression in human keratinocytes through Toll-like receptors. J Invest Dermatol 2005; 124: 931–8 MEDLINE CrossRef|
|e50.||Alexeyev O, Lundskog B, Ganceviciene R, et al.: Pattern of tissue invasion by Propionibacterium acnes in acne vulgaris. J Derm Sci 2012; 67: 63–6 MEDLINE CrossRef|
|e51.||Jahns AC, Lundskog B, Ganceviciene R, et al.: An increased incidence of Propionibacterium acnes biofilms in acne vulgaris: a case control study. Br J Dermatol 2012; 167: 50–8 MEDLINE CrossRef|
|e52.||Stüttgen G: Zur Lokalbehandlung von Keratosen mit Vitamin A-Säure. Dermatologica 1962; 124: 65–80 CrossRef|
|e53.||Schumacher A, Stüttgen G: Vitamin-A-Säure bei Hyerkeratosen, epithelialen Tumoren und Akne. Deutsch Med Wschr 1971; 96: 1547–51 MEDLINE CrossRef|
|e54.||Peck GL, Olsen TG, Yoder FW, et al.: Prolonged remissions of cystic and conglobate acne with 13-cis retinoic acid. N Engl J Med 1979; 300: 329–33 MEDLINE CrossRef|
|e55.||Sapadin AN, Fleischmajer R: Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad Dermatol 2006; 54: 258–65 MEDLINE CrossRef|
|e56.||Zouboulis CC: The truth behind this undeniable efficacy—recurrence rates and relapse risk factors of acne treatment with oral isotretinoin. Dermatology 2006; 212: 99–100 MEDLINE CrossRef|
|e57.||Orfanos CE, Zouboulis CC: Oral retinoids in the treatment of seborrhoea and acne. Dermatology 1998; 196: 140–7 CrossRef|
|e58.||Zouboulis CC, Piquero-Martin J: Update and future of systemic acne treatment. Dermatology 2003; 206: 37–53.e74.|
|e59.||Goldstein JA, Comite H, Mescon H, Pochi PE: Isotretinoin in the treatment of acne: histologic changes, sebum production, and clinical observations. Arch Dermatol 1982; 118: 555–8 CrossRef|
|e60.||Jones DH, King K, Miller AJ, Cunliffe WJ: A dose-response study of 13-cis-retinoic acid in acne vulgaris. Br J Dermatol 1983;108:333–43 CrossRef|
|e61.||Hennes R, Mack A, Schell H, Vogt HJ: 13-cis-retinoic acid in conglobate acne. A follow-up study of 14 trial centers. Arch Dermatol Res 1984; 276: 209–15 MEDLINE CrossRef|
|e62.||Harms M, Masouye I, Radeff B: The relapses of cystic acne after isotretinoin treatment are age-related: a long-term follow-up study. Dermatologica. 1986; 172: 148–53 CrossRef|
|e63.||Cunliffe WJ, Norris JF: Isotretinoin – an explanation for its long-term benefit. Dermatologica 1987; 175(suppl 1): 133–7 MEDLINE CrossRef|
|e64.||Chivot M, Midoun H: Isotretinoin and acne—a study of relapses. Dermatologica 1990; 180: 240–3 CrossRef|
|e65.||Layton AM, Knaggs H, Taylor J, Cunliffe WJ: Isotretinoin for acne vulgaris—10 years later: A safe and successful treatment. Br J Dermatol 1993; 129: 292–6 CrossRef|
|e66.||Lehucher-Ceyrac D, Weber-Buisset MJ: Isotretinoin and acne in practice: a prospective analysis of 188 cases over 9 years. Dermatology 1993; 186: 123–8 CrossRef|
|e67.||Lehucher-Ceyrac D, de La Salmoniere P, Chastang C, Morel P: Predictive factors for failure of isotretinoin treatment in acne patients: results from a cohort of 237 patients. Dermatology 1999; 198: 278–83 CrossRef|
|e68.||Shahidullah M, Tham SN, Goh CL: Isotretinoin therapy in acne vulgaris: a 10-year retrospective study in Singapore. Int J Dermatol 1994; 33: 60–3 CrossRef|
|e69.||Goulden V, Clark SM, McGeown C, Cunliffe WJ: Treatment of acne with intermittent isotretinoin. Br J Dermatol 1997; 137: 106–8 CrossRef|
|e70.||Quéreux G, Volteau C, N’Guyen JM, Dréno B: Prospective study of risk factors of relapse after treatment of acne with oral isotretinoin. Dermatology 2006; 212: 168–76 MEDLINE CrossRef|
|e71.||Karadag AS, Bilgili SG, Selvi Y, et al.: Effects of isotretinoin treatment on general psychiatric symptoms, quality of life and social phobia in acne vulgaris patients. J Eur Acad Dermatol Venereol 2013; 27: 260–1 MEDLINE CrossRef|
|e72.||Rubinow DR, Peck GL, Squillace KM, Gantt GG: Reduced anxiety and depression in cystic acne patients after successful treatment with oral isotretinoin. J Am Acad Dermatol 1987; 17: 25–32 CrossRef|
|e73.||Bernstein CN, Nugent Z, Longobardi T, Blanchard JF: Isotretinoin is not associated with inflammatory bowel disease: a population-based case-control study. Am J Gastroenterol 2009; 104: 2774–8 MEDLINE CrossRef|
|e74.||Zouboulis CC: Acne: Current aspects on pathology and treatment. Dermatol Experiences 1999; 1: 6–37.|
|e75.||Crockett SD, Porter CQ, Martin CF, et al.: Isotretinoin use and the risk of inflammatory bowel disease: a case-control study. Am J Gastroenterol 2010; 105: 1986–93 MEDLINE PubMed Central CrossRef|